The mammalian cochlea is one of the least accessible organs for drug delivery. Systemic 11 administration of many drugs, notably the most frequently used corticosteroids and 12 aminoglycoside antibiotics, is severely limited by the blood-labyrinth barrier. Local 13 intratympanic administration into the middle ear would be a preferable option in this case and 14 the only option for many old and newly emerging classes of drugs and therapies including local 15 anaesthetics, antioxidants, apoptosis inhibitors, neurotransmitters and their antagonists, 16 monoclonal antibodies, growth factors, signalling pathway regulators and genetic material. 17 Intratympanic administration of drugs relies on their remaining in contact with the cochlear 18 round window membrane long enough to allow their diffusion into the cochlea fluid. The 19 ability of drugs to pass through the round window does not, however, lead to their effective 20 distribution along the long and narrow cochlear spiral. This slow technique leads to steady-21 state, base-to-apex concentration gradients that are orders of magnitude and well outside the 22 therapeutic windows for many drugs. Here we present an efficient, quick, reliable and simple 23 method that can consistently and uniformly deliver drugs along the entire length of the intact 24 cochlea within minutes without disrupting cochlear boundaries. This novel method combines 25 middle ear drug administration and cochlear pumping, through large amplitude, low-frequency 26 reciprocal oscillations of the stapes and round window. Our preliminary experiments using 27 salicylate as a model drug with well-established physiological effect demonstrate the 28 exceptionally high efficiency of the method for drug delivery to the cochlear apex. In the short 29 term, the presented method should lead to significant improvements in the efficacy and 30 reliability of currently employed drugs for the treatment of sensorineural hearing loss, 31 Menière's disease, noise-induced hearing loss, tinnitus and autoimmune inner ear disease. In 32 the longer term, the outcomes of our research should facilitate new and novel ways of 33 approaching the treatment of inner ear disorders since we have overcome the challenge of 34 delivering of therapeutics along the entire length of the cochlea. 35 INTRODUCTION 36 Reliable, efficient and uniform drug delivery into the cochlea remains an unsolved challenge 37 and is a major barrier to the prevention or treatment of inner ear disorders. The mammalian 38 cochlea is one of the least accessible organs for drug delivery (Salt and Plontke, 2009; Hao and 39 Li, 2019). Systemic administration of many drugs, notably the most frequently used 40 corticosteroids and aminoglycoside antibiotics, is severely limited by the blood-labyrinth 41 barrier (Salt and Hirose, 2018; Nyberg et al., 2019). Direct injection into the cochlea is limited 42 by the requirement for surgical interventions, and, significantly, does not guarantee uniform 43 drug delivery along the cochlea. 44 There has been an increase in the number of therapeutic compounds with potential to treat inner 45 ear disorders. This comprises old and newly emerging classes of drugs and therapies including 46 corticosteroids, local anaesthetics, antioxidants, apoptosis inhibitors, neurotransmitters and 47 their antagonists, monoclonal antibodies, growth factors, signalling pathway regulators and 48 genetic material (Hao and Li, 2019; Devare et al., 2018). A recent review identified 43 biotech 49 companies currently pursuing experimental compounds for inner ear therapy (Schilder et al., 50 2019). All such efforts depend on a technique allowing reliable delivery of such compounds 51 uniformly along the entire length of the cochlea. 52 Intratympanic administration of drugs (Schuknecht, 1956; Patel et al., 2019; Rybak et al., 2019) 53 relies on their remaining in contact with the round window membrane (RW, a membranous 54 opening in the bony wall of the cochlear into the middle ear) long enough to enable their 55 diffusion into the perilymph of the scala tympani (ST) (Figure 1A). The ability of drugs to 56 pass through the RW does not, however, guarantee their effective distribution along the 57 cochlear spiral. Drug distribution in the ST is limited by the low flow rate of perilymph within 58 the cochlea (Ohyama et al., 1988) and is dominated by passive diffusion which is constrained 59 by cochlear geometry (Figure 1A) . 60 Combined direct measurements, morphological studies and computer modelling revealed that 61 the difference in concentration of drugs between the cochlear base and apex was many orders from the vibrometer was low-pass filtered at 100 kHz, with a sensitivity of 5 mm/s/V. Stapes 123 displacement was found by integrating the velocity responses off-line.
of magnitude when drugs entered the ST through the RW and diffused passively to the apex (Saijo and Kimura, 1984; Salt and Ma, 2001; Imamura and Adams, 2003; Mynatt et al., 2006; et al., 2018) . Retention of drugs near the RW in the middle ear cavity for an arbitrary long time 66 (Piu and Bishop, 2019) , once thought to be a means of overcoming the large concentration 67 gradients, does not decrease concentration gradients along the cochlea. It only stabilizes them 68 (Sadreev et al., 2019) . Here we show that the same characteristics of the cochlear geometry 69 that restricts passive basal-apical diffusion, together with cochlear hydrodynamics, promotes 70 the even distribution of substances along the entire cochlear length. This enables drugs to reach 71 apical cochlear regions essential for communication and localization (Nuttall et al., 2018) .
72

Methods
73
Animals
74
Animal preparation and signal generation and recording have been described elsewhere 75 (Burwood et al., 2017) . Briefly, pigmented guinea pigs of similar weight (350-360 g) and both 76 sexes were anaesthetised with the neurolept anaesthetic technique (0.06 mg/kg body weight 77 atropine sulphate s.c., 30 mg/kg pentobarbitone i.p., 500 l/kg Hypnorm i.m.). Additional 78 injections of Hypnorm were given every 40 minutes. Additional doses of pentobarbitone were 79 administered as needed to maintain a non-reflexive state. The heart rate was monitored with a 80 pair of skin electrodes placed on both sides of the thorax. The animals were tracheotomized 81 and artificially respired with a mixture of O2/CO2, and their core temperature was maintained 82 at 38C with a heating blanket and a heated head holder. All procedures involving animals 83 were performed in accordance with UK Home Office regulations with approval from the 84 University of Brighton Animal Welfare and Ethical Review Body.
85
Signal generation and recording 86 The middle ear cavity of the ear used for the measurements and salicylate application was 87 opened to reveal the RW. Compound action potentials (CAPs) of the auditory nerve in response 88 to pure tone stimulation were measured from the cochlear bony ridge in the proximity of the 89 RW membrane using Teflon-coated silver wire coupled to laboratory designed and built 90 extracellular amplifier (James Hartley). Thresholds of the N1 peak of the CAP at different 91 frequencies which corresponds to different distances from the cochlear base (Greenwood, 92 1990) were estimated visually using 10 ms pure tone stimuli at a repetition rate of 10 Hz. microphones were coupled to the ear canal via 1 cm long, 4 mm diameter tubes to a conical 97 speculum, the 1 mm diameter opening of which was placed about 1 mm from the tympanum.
98
The speculum was sealed in the ear canal. The closed sound system was calibrated in situ for 99 frequencies between 1 and 50 kHz. Known sound pressure levels were expressed in dB SPL re 100 210 -5 Pa.
101
All acoustic stimuli in this work were shaped with raised cosines of 0.5 ms duration at the 102 beginning and at the end of stimulation. White noise for acoustical calibration and tone 103 sequences for auditory stimulation were synthesised by a Data Translation 3010 board at 250 104 kHz and delivered to the microphones through low-pass filters (100 kHz cut-off frequency).
105
Signals from the acoustic measuring amplifier (James Hartley) were digitised at 250 kHz using 5 preparations (Sadreev et al., 2019) . Pressure oscillations at 4 Hz were applied to the ear canal during 5 minutes before each red non-zero time point plotted to cause large-amplitude (~50 µm) stapes movement and the CAP thresholds were measure during following 5minute interval without pressure oscillation. Frequency of acoustic stimulation is indicated within each panel. 5 l of 100 mM salicylate solution were applied to the RW at time zero. Grey lines near the horizontal axis indicate statistically significant (p < 0.05, unpaired ttest) differences between data for the cochlear pumping and passive diffusion within consecutive 10-minute intervals. Some of the passive diffusion data have been presented before (Sadreev et al., 2019) . 
